Skip to main content
Figure 3 | BMC Veterinary Research

Figure 3

From: A fully caninised anti-NGF monoclonal antibody for pain relief in dogs

Figure 3

Characterisation of the caninised anti-NGF antibody NV-01. A) SDS-PAGE of reduced (R) and non-reduced (NR) NV-01. B) Stability of NV-01 determined by size-exclusion chromatography following storage at −20 degrees or room temperature (RT) for 3 months. C) Binding affinity of NV-01 to immobilized NGF. Various concentrations of NV-01 (500 nM, 250 nM, 125 nM, 62.5 nM and 31.25 nM) were passed over NGF for 60 seconds then the flow switched to buffer. D) Inhibition of NGF induced proliferation of TF-1 cells in vitro.1 ng/ml NGF was incubated with NV-01 or an irrelevant IgG control antibody at concentrations ranging from 2.5 ng/ml to 0.002 ng/ml.

Back to article page